CN111372921B - 小分子化合物 - Google Patents

小分子化合物 Download PDF

Info

Publication number
CN111372921B
CN111372921B CN201880070789.4A CN201880070789A CN111372921B CN 111372921 B CN111372921 B CN 111372921B CN 201880070789 A CN201880070789 A CN 201880070789A CN 111372921 B CN111372921 B CN 111372921B
Authority
CN
China
Prior art keywords
disease
cancer
cpt
condition
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880070789.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372921A (zh
Inventor
鹿炳伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celepate Corp
Original Assignee
Celepate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celepate Corp filed Critical Celepate Corp
Publication of CN111372921A publication Critical patent/CN111372921A/zh
Application granted granted Critical
Publication of CN111372921B publication Critical patent/CN111372921B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201880070789.4A 2017-09-13 2018-09-12 小分子化合物 Active CN111372921B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (2)

Publication Number Publication Date
CN111372921A CN111372921A (zh) 2020-07-03
CN111372921B true CN111372921B (zh) 2023-12-01

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070789.4A Active CN111372921B (zh) 2017-09-13 2018-09-12 小分子化合物

Country Status (9)

Country Link
US (3) US11186550B2 (https=)
EP (1) EP3681874B1 (https=)
JP (1) JP7170341B2 (https=)
KR (1) KR102644045B1 (https=)
CN (1) CN111372921B (https=)
AU (1) AU2018331371C1 (https=)
CA (1) CA3075649A1 (https=)
IL (1) IL273242B2 (https=)
WO (1) WO2019055528A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound
CA3131294A1 (en) * 2019-02-27 2020-09-03 Cerepeut, Inc. Quinazolinone compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
US20150017262A1 (en) * 2011-04-19 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibition of dynamin related protein 1 to promote cell death
US20150164896A1 (en) * 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368434B2 (en) 2002-06-27 2008-05-06 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of ALDH
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US8759097B2 (en) * 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN105008515A (zh) 2012-12-28 2015-10-28 小利兰·斯坦福大学托管委员会 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
US20150017262A1 (en) * 2011-04-19 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibition of dynamin related protein 1 to promote cell death
US20150164896A1 (en) * 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Inhibition of the Mitochondrial Division Dynamin Reveals Its Role in Bax/Bak-Dependent Mitochondrial Outer Membrane Permeabilization;Ann Cassidy-Stone et al.;《Developmental Cell》;193-204 *

Also Published As

Publication number Publication date
US11186550B2 (en) 2021-11-30
US11912669B2 (en) 2024-02-27
KR20200053560A (ko) 2020-05-18
US20220340534A1 (en) 2022-10-27
JP2020533399A (ja) 2020-11-19
IL273242B2 (en) 2023-08-01
AU2018331371A1 (en) 2020-04-02
AU2018331371C1 (en) 2024-05-09
US12404251B2 (en) 2025-09-02
IL273242A (en) 2020-04-30
KR102644045B1 (ko) 2024-03-05
IL273242B1 (en) 2023-04-01
JP7170341B2 (ja) 2022-11-14
EP3681874A1 (en) 2020-07-22
WO2019055528A1 (en) 2019-03-21
AU2018331371B2 (en) 2024-02-15
EP3681874B1 (en) 2022-04-06
EP3681874A4 (en) 2021-01-13
CN111372921A (zh) 2020-07-03
US20240246919A1 (en) 2024-07-25
US20200216400A1 (en) 2020-07-09
CA3075649A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
US12404251B2 (en) Small molecule compound
EP2609082A1 (de) Imidazo [4,5-c]chinoline als dna-pk-inhibitoren
KR20210021534A (ko) 라파마이신 유사체 및 이의 용도
DE102010025786A1 (de) Pyrazolochinoline
US11987568B2 (en) Allosteric inhibitor of WEE1 kinase
US20170334842A1 (en) Inhibitors of the mitf molecular pathway
US12454514B2 (en) Quinazolinone compounds
CN113395968B (zh) 用于治疗疾病的fak抑制剂和btk抑制剂的组合
AU2022354697A1 (en) Cannabinoids c- and o-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof
US10512631B2 (en) Chalcone compounds
US8729053B2 (en) Nuclear factor kappa B pathway inhibitor composition and use of same
WO2014057511A1 (en) Use of emicorons as selective inducers of damage to the telomere dna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant